HealthInvest Partners AB Has $2.94 Million Stock Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD)

HealthInvest Partners AB lifted its stake in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 85.9% during the 3rd quarter, HoldingsChannel reports. The firm owned 275,472 shares of the biopharmaceutical company’s stock after acquiring an additional 127,265 shares during the period. Amicus Therapeutics comprises 1.4% of HealthInvest Partners AB’s investment portfolio, making the stock its 22nd largest position. HealthInvest Partners AB’s holdings in Amicus Therapeutics were worth $2,942,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. OLD Second National Bank of Aurora acquired a new position in Amicus Therapeutics in the 3rd quarter valued at approximately $26,000. Hazlett Burt & Watson Inc. increased its position in shares of Amicus Therapeutics by 156.9% during the third quarter. Hazlett Burt & Watson Inc. now owns 2,569 shares of the biopharmaceutical company’s stock worth $28,000 after buying an additional 1,569 shares during the period. Blue Trust Inc. raised its stake in Amicus Therapeutics by 1,705.4% during the third quarter. Blue Trust Inc. now owns 2,997 shares of the biopharmaceutical company’s stock worth $30,000 after buying an additional 2,831 shares during the last quarter. Arcadia Investment Management Corp MI acquired a new position in Amicus Therapeutics in the third quarter valued at $32,000. Finally, Headlands Technologies LLC bought a new stake in Amicus Therapeutics during the second quarter valued at $89,000.

Amicus Therapeutics Price Performance

FOLD traded down $0.04 during midday trading on Thursday, hitting $9.55. The stock had a trading volume of 7,443 shares, compared to its average volume of 2,711,203. The business has a fifty day moving average of $10.89 and a 200 day moving average of $10.59. The company has a quick ratio of 2.42, a current ratio of 3.15 and a debt-to-equity ratio of 2.18. Amicus Therapeutics, Inc. has a 1 year low of $9.02 and a 1 year high of $14.57.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on the company. Jefferies Financial Group initiated coverage on Amicus Therapeutics in a research report on Friday, September 6th. They issued a “buy” rating and a $18.00 price objective for the company. StockNews.com upgraded shares of Amicus Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, November 16th. Bank of America boosted their target price on Amicus Therapeutics from $13.00 to $15.00 and gave the company a “buy” rating in a research report on Thursday, October 17th. Morgan Stanley reduced their price objective on Amicus Therapeutics from $19.00 to $18.00 and set an “overweight” rating for the company in a research note on Friday, October 11th. Finally, JPMorgan Chase & Co. boosted their price objective on Amicus Therapeutics from $16.00 to $17.00 and gave the stock an “overweight” rating in a report on Tuesday, November 12th. One equities research analyst has rated the stock with a hold rating and nine have issued a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $17.63.

Insider Activity at Amicus Therapeutics

In related news, CEO Bradley L. Campbell sold 7,500 shares of the company’s stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $11.71, for a total transaction of $87,825.00. Following the completion of the transaction, the chief executive officer now owns 886,654 shares in the company, valued at $10,382,718.34. This represents a 0.84 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders sold 30,401 shares of company stock worth $352,038 in the last ninety days. 2.20% of the stock is owned by company insiders.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.